CASI Pharmaceuticals, Inc. (NASDAQ:CASI) traded down 16.5% during trading on Wednesday . The stock traded as low as $3.20 and last traded at $3.34. 1,309,092 shares were traded during trading, an increase of 386% from the average session volume of 269,617 shares. The stock had previously closed at $4.00.
Several equities research analysts recently commented on the company. Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 14th. ValuEngine raised CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 15th. Finally, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of CASI Pharmaceuticals in a research report on Friday, September 8th.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. analysts anticipate that CASI Pharmaceuticals, Inc. will post -0.15 earnings per share for the current fiscal year.
In other CASI Pharmaceuticals news, Director Wei-Wu He purchased 100,000 shares of the firm’s stock in a transaction on Tuesday, October 10th. The shares were purchased at an average price of $1.95 per share, for a total transaction of $195,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders acquired 996,329 shares of company stock worth $1,647,138. 24.52% of the stock is currently owned by company insiders.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.